Dimethyl Fumarate Alleviates NLRP3 Inflammasome Activation in Microglia and Sickness Behavior in LPS-Challenged Mice

Bora Tastan1,2, Burak I Arioz1,2, Kemal Ugur Tufekci1,3

  • 1Genc Laboratory, Izmir Biomedicine and Genome Center, Izmir, Turkey.

Frontiers in Immunology
|December 3, 2021
PubMed

Insights

Dimethyl fumarate (DMF) effectively reduces microglial NLRP3 inflammasome activation, a key factor in sickness behavior. This immunomodulatory compound ameliorates inflammation and improves behavior in LPS-induced models.

Area of Science:

  • Neuroimmunology
  • Inflammation research
  • Pharmacology

Background:

  • NLRP3 inflammasome activation is implicated in pathogenic conditions like lipopolysaccharide (LPS)-induced sickness behavior.
  • Dimethyl fumarate (DMF) possesses immunomodulatory and anti-oxidative properties, with established therapeutic uses.

Purpose of the Study:

  • To investigate the efficacy of DMF in mitigating microglial NLRP3 inflammasome activation both in vitro and in vivo.
  • To elucidate the underlying mechanisms of DMF's action on inflammatory pathways and behavior.

Main Methods:

  • In vitro studies utilized LPS- and ATP-stimulated N9 microglial cells to assess inflammasome markers, pyroptosis, ROS, and Nrf2/NF-κB pathways.
  • In vivo studies involved LPS-challenged male mice treated with DMF, assessing behavioral changes and NLRP3/Caspase-1 expression in microglia.
  • MicroRNA expression (miR-146a, miR-155) was also evaluated.

Main Results:

  • DMF significantly reduced LPS/ATP-induced NLRP3 inflammasome activation markers (IL-1β, IL-18, caspase-1, NLRP3), ROS formation, and pyroptotic cell death in microglia.
  • DMF treatment ameliorated LPS-induced sickness behavior in mice and decreased NLRP3/caspase-1 levels via Nrf2 activation.
  • DMF pretreatment also led to a decrease in miR-146a and miR-155 expression.

Conclusions:

  • DMF demonstrates significant potential in ameliorating microglial NLRP3 inflammasome activation and associated pathologies.
  • The findings support DMF's therapeutic utility in diseases driven by NLRP3 inflammasome hyperactivity.
  • This study provides mechanistic insights into DMF's anti-inflammatory effects via Nrf2 activation and modulation of specific microRNAs.

Related Concept Videos